-
CME Accreditation from UEMS-EACCME and the Accreditation Council of Oncology in Europe is being applied for. CME Accreditation recognises the high quality of a meeting from an educational and scientific perspective.
CME Accreditation from UEMS-EACCME and the Accreditation Council of Oncology in Europe is being applied for. CME Accreditation recognises the high quality of a meeting from an educational and scientific perspective.
The EACR-OECI Conference on Precision Medicine for Cancer will be held from 1 – 4 March 2015 at Neumünster Abbey, Luxembourg.
Recent advances in technology have provided an unprecedented opportunity to develop platforms for implementing precision/personalised medicine in cancer. This conference will discuss the challenges that face us in implementing these approaches.
Although our understanding of the pathogenesis of cancer has advanced enormously in recent years, we have only just begun to successfully translate this into improvements in the clinical management of patients. A significant opportunity is offered by the knowledge that cancer cells are ‘addicted’ to certain altered genes, a vulnerability that can be exploited therapeutically. A number of cancer-causing genes have been identified that are recurrently altered and stimulate tumour growth. These ‘driver genes’ correspond to oncogenes (or tumour suppressor genes) that are mutated or deregulated (e.g., amplified), causing the tumour to become dependent on the lesion(s) for survival and/or proliferation.
Topics to be covered include:Who should attend?
This meeting is of interest to fundamental, translational and clinical cancer researchers alike, as it will cover several aspects of precision treatment of cancer, ranging from tumour heterogeneity and novel metabolic targets to circulating tumour cells and new drug target discovery strategies.
Background to the conference topic
Cancers are increasingly classified in terms of the ensemble of mutant genes they harbour, and targeting such genes with ‘precision’ inhibitors has resulted in profound clinical impact. The extent, duration and rate of responses can be unprecedented. Despite these advances, a large number of cancers treated with single agents become resistant soon after commencing treatment. This is caused by several mechanisms, including the pre-existence of genetic alterations in heterogeneous tumours. Thus, although significant progression has been made in identifying critical genetic factors serving as potential cancer liabilities, real benefits to patients have been modest.
We look forward to welcoming you to Luxembourg for this exciting conference.
EUR
We don’t accept Online Abstracts
We are pleased to offer accommodation at a special rate for participants at a number
Bookings can be made online through a dedicated web page set up by the Luxembourg Convention Bureau. You will need the access code EACR15 to make your booking.
Book here: https://conventions.lcto.lu/en/eacr-precision-medicine-for-cancer
Deadline
If you have any questions about
Seven proffered papers will be selected from submitted abstracts for oral presentation.
All abstracts will be reviewed by the Scientific Programme Committee and successful delegates will be notified of their poster or oral presentation as soon as possible after 1 January 2015.
Poster specifications: Poster Boards are ‘portrait’ 1m wide by 2m high. Your poster should be no greater than 90cm x 140cm in portrait. You can attach your poster with drawing pins or double-sided Velcro tape which will be provided for you.